Fortis Therapeutics, Inc.
Fortis Therapeutics, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | Digestive System Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, digestive system disorder, hypertrophic pyloric stenosis, neoplasm, nerve sheath neoplasm, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, pyloric stenosis, stomach disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-10-01 | NCT07664397 | |
| FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-17 | NCT05011188 | |
| PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 | 2026-03-17 | NCT05245006 |